HUE050567T2 - Triciklusos heterociklusok rák kezelésére - Google Patents

Triciklusos heterociklusok rák kezelésére

Info

Publication number
HUE050567T2
HUE050567T2 HUE16770011A HUE16770011A HUE050567T2 HU E050567 T2 HUE050567 T2 HU E050567T2 HU E16770011 A HUE16770011 A HU E16770011A HU E16770011 A HUE16770011 A HU E16770011A HU E050567 T2 HUE050567 T2 HU E050567T2
Authority
HU
Hungary
Prior art keywords
cancer
treatment
tricyclic heterocycles
tricyclic
heterocycles
Prior art date
Application number
HUE16770011A
Other languages
English (en)
Hungarian (hu)
Inventor
Patrick Angibaud
Diego Broggini
Helene Colombel
Filip Cuyckens
Steven Hostyn
Russell Jones
Olivier Querolle
Wim Vermeulen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE050567T2 publication Critical patent/HUE050567T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE16770011A 2015-09-23 2016-09-22 Triciklusos heterociklusok rák kezelésére HUE050567T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15186491 2015-09-23

Publications (1)

Publication Number Publication Date
HUE050567T2 true HUE050567T2 (hu) 2020-12-28

Family

ID=54196892

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16770011A HUE050567T2 (hu) 2015-09-23 2016-09-22 Triciklusos heterociklusok rák kezelésére

Country Status (17)

Country Link
US (1) US11155555B2 (enExample)
EP (1) EP3353177B1 (enExample)
JP (1) JP6898919B2 (enExample)
KR (1) KR102703498B1 (enExample)
CN (1) CN108026095B (enExample)
AU (1) AU2016328692B2 (enExample)
BR (1) BR112018005637B1 (enExample)
CA (1) CA2996857C (enExample)
DK (1) DK3353177T3 (enExample)
ES (1) ES2811845T3 (enExample)
HR (1) HRP20201157T1 (enExample)
HU (1) HUE050567T2 (enExample)
LT (1) LT3353177T (enExample)
MX (1) MX382919B (enExample)
RU (1) RU2747645C2 (enExample)
SI (1) SI3353177T1 (enExample)
WO (1) WO2017050864A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN108445033B (zh) * 2018-01-16 2020-01-31 温州大学 一种4-(3h)喹唑啉酮类化合物的生物碱光学纯度的测定方法
JP7378488B2 (ja) * 2019-03-08 2023-11-13 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｆｇｆｒ４キナーゼ阻害剤、その製造方法及び用途
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) * 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN113024518A (zh) * 2019-12-09 2021-06-25 武汉九州钰民医药科技有限公司 一种厄达替尼的制备方法
CN113024517A (zh) * 2019-12-09 2021-06-25 武汉九州钰民医药科技有限公司 一种制备厄达替尼的方法
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4352060A1 (en) * 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
GB1583753A (en) 1976-07-14 1981-02-04 Science Union & Cie Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5843941A (en) 1993-05-14 1998-12-01 Genentech, Inc. Ras farnesyl transferase inhibitors
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
US6626901B1 (en) 1997-03-05 2003-09-30 The Trustees Of Columbia University In The City Of New York Electrothermal instrument for sealing and joining or cutting tissue
CZ296845B6 (cs) 1997-05-28 2006-07-12 Aventis Pharmaceuticals Inc. Derivát chinolinu a chinoxalinu, farmaceutický prostredek obsahující tento derivát a pouzití
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
WO2000055153A1 (en) 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
CA2393896A1 (en) 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2002359714B2 (en) 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
ES2333702T3 (es) 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
JP2003213463A (ja) 2002-01-17 2003-07-30 Sumitomo Chem Co Ltd 金属腐食防止剤および洗浄液
WO2003076416A1 (en) 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
AU2003223467B2 (en) 2002-04-08 2007-10-04 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7265378B2 (en) 2002-07-10 2007-09-04 E. I. Du Pont De Nemours And Company Electronic devices made with electron transport and/or anti-quenching layers
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
KR20050056227A (ko) 2002-10-03 2005-06-14 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
US7504391B2 (en) 2003-05-22 2009-03-17 Schering Corporation Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders
RU2330851C9 (ru) 2003-05-23 2008-10-20 Центарис Гмбх ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
EP1646383A4 (en) 2003-07-21 2009-03-25 Bethesda Pharmaceuticals Inc DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
US7511145B2 (en) 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
EP1673092B1 (en) 2003-10-17 2007-08-15 4 Aza Ip Nv Heterocycle-substituted pteridine derivatives and their use in therapy
JP4890255B2 (ja) 2003-11-07 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
MXPA06005687A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
JP2007512275A (ja) 2003-11-24 2007-05-17 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾリルおよびイミダゾリルピリミジン
MXPA06007326A (es) 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
BRPI0514691A (pt) 2004-08-31 2008-06-17 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
CN101039946B (zh) * 2004-10-13 2010-12-08 霍夫曼-拉罗奇有限公司 用作用于cdk2和血管生成的抑制剂及用于治疗乳腺、结肠、肺和前列腺癌的二取代吡唑并苯并二氮杂*类
MX2007004276A (es) 2004-10-14 2007-05-16 Hoffmann La Roche 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.
JP2008516939A (ja) 2004-10-15 2008-05-22 アストラゼネカ アクチボラグ 化学化合物
EP1830869B1 (en) 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
CA2597447C (en) 2005-02-14 2014-03-25 Bionomics Limited Novel tubulin polymerisation inhibitors
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
CA2606017A1 (en) 2005-05-12 2006-11-23 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1881981A1 (en) 2005-05-18 2008-01-30 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
MX2008002723A (es) 2005-08-26 2008-03-26 Serono Lab Derivados de pirazina y uso como inhibidores de p13k.
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
EP1957487A1 (de) 2005-11-11 2008-08-20 AEterna Zentaris GmbH Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
EP1966214B9 (en) 2005-12-21 2017-09-13 Janssen Pharmaceutica N.V. Triazolopyridazines as tyrosine kinase modulators
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
CA2653117A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituted pteridines substituted with a four-membered heterocycle
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
JP2009541460A (ja) 2006-07-03 2009-11-26 ベレナギング ヴォー クリスタラク ホガー オンダーヴェイル ヴェーテンザパーリク オンダージーク エン パシェンテンゾーク ヒスタミンｈ４受容体と相互作用する縮合二環式化合物
JP2008127446A (ja) 2006-11-20 2008-06-05 Canon Inc １，５−ナフチリジン化合物及び有機発光素子
WO2008076278A2 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
AU2007337886C1 (en) 2006-12-22 2014-10-16 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
EP2172450B9 (en) 2007-06-20 2014-10-08 Mitsubishi Tanabe Pharma Corporation Novel malonic acid sulfonamide derivative and pharmaceutical use thereof
WO2008155378A1 (en) 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
EP2173338A1 (en) 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
US7981903B2 (en) 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
EP2173354A4 (en) 2007-08-09 2011-10-05 Glaxosmithkline Llc CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
EP2282995B1 (en) 2008-05-23 2015-08-26 Novartis AG Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
CA2750047A1 (en) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
EP2391623A4 (en) 2009-02-02 2012-09-05 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8310836B2 (en) 2009-05-21 2012-11-13 Ocz Technology Group, Inc. Mass storage device for a computer system and method therefor
HRP20230248T1 (hr) 2009-06-12 2023-04-14 Abivax Spojevi korisni za liječenje preranog starenja, te naročito progerije
CA2772714C (en) 2009-09-03 2017-09-26 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011047129A1 (en) 2009-10-15 2011-04-21 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011149937A1 (en) 2010-05-24 2011-12-01 Intellikine, Inc. Heterocyclic compounds and uses thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
EP2670753B1 (en) 2011-01-31 2016-10-19 Novartis AG Novel heterocyclic derivatives
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
CN105693645B (zh) 2011-05-10 2018-10-09 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
JP6002223B2 (ja) 2011-08-26 2016-10-05 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
EP3332785B1 (en) 2011-09-14 2020-05-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
KR102106962B1 (ko) 2012-03-08 2020-05-07 아스테라스 세이야쿠 가부시키가이샤 신규 fgfr3 융합체
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN105683197B (zh) 2013-08-02 2019-12-27 亚尼塔公司 单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX370099B (es) 2014-03-26 2019-12-02 Astex Therapeutics Ltd Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
KR20170137717A (ko) 2015-02-19 2017-12-13 바이오클린 테라퓨틱스, 인크. 암의 치료를 위한 방법, 조성물, 및 키트
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017050865A1 (en) * 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN107103171B (zh) 2016-02-19 2020-09-25 阿里巴巴集团控股有限公司 机器学习模型的建模方法及装置

Also Published As

Publication number Publication date
WO2017050864A1 (en) 2017-03-30
HK1254965A1 (zh) 2019-08-02
CN108026095A (zh) 2018-05-11
US11155555B2 (en) 2021-10-26
AU2016328692B2 (en) 2021-03-11
BR112018005637A2 (enExample) 2018-10-02
US20200255430A1 (en) 2020-08-13
EP3353177A1 (en) 2018-08-01
DK3353177T3 (da) 2020-08-24
SI3353177T1 (sl) 2020-08-31
JP2018527388A (ja) 2018-09-20
BR112018005637B1 (pt) 2023-11-28
ES2811845T3 (es) 2021-03-15
LT3353177T (lt) 2020-08-25
HRP20201157T1 (hr) 2020-11-13
AU2016328692A1 (en) 2018-03-01
RU2018113718A3 (enExample) 2019-12-24
MX2018003563A (es) 2018-06-18
KR20180052623A (ko) 2018-05-18
RU2018113718A (ru) 2019-10-23
KR102703498B1 (ko) 2024-09-04
RU2747645C2 (ru) 2021-05-11
CA2996857A1 (en) 2017-03-30
CA2996857C (en) 2024-05-21
CN108026095B (zh) 2021-07-27
JP6898919B2 (ja) 2021-07-07
MX382919B (es) 2025-03-13
EP3353177B1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL256224B (en) Combined therapy for cancer treatment
SG11201609770TA (en) Combination therapies for the treatment of cancer
IL261959A (en) Cancer treatment with tg02
IL259996A (en) Combinations for cancer treatment
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL258521A (en) Combination of treatments for cancer treatment
IL285077A (en) Compounds for the treatment of cancer
SI3353177T1 (sl) Triciklični heterocikli za zdravljenje raka
SMT202100245T1 (it) Trattamento combinato del cancro
IL263835A (en) Exosome-guided treatment of cancer
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL260814A (en) Cancer treatment
ZA201606921B (en) Use of xanthophylls for the treatment of cancers
GB201522433D0 (en) Cancer treatment
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL255167A0 (en) Compounds for the treatment of cancer
ZA201704589B (en) Compounds for the treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer